HSP90AA1 and metabolic dysfunction-associated steatotic liver disease: Recently, it has been reported that inhibition of Hsp90 suppresses lipid synthesis via directly promoting the degradation of sterol regulatory element-binding protein 1 (SREBP1) and SREBP2.77–79 Here, our study proposes an independent mechanism by which the Hsp90 inhibitors function in the treatment of NAFLD and obesity.